➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Baxter
Express Scripts
Harvard Business School
Johnson and Johnson

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

Claims for Patent: 5,538,885

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,538,885
Title: Expression systems
Abstract:Expression systems which comprise a mammalian host, such as erythroid cells, transformed with a vector which comprises a promoter, a DNA sequence which codes for a desired polypeptide and a dominant control region. The vectors and methods for preparing polypeptides using the expression systems are also described. In a preferred embodiment, the vector contains cDNA for the desired polypeptide and a sequence which is capable of stabilising mRNA produced from the cDNA. The expression systems are particularly efficient and are capable of secreting the desired polypeptide.
Inventor(s): Hollis; Melvyn (Cheshire, GB2), Needham; Maurice R. C. (Cheshire, GB2), Gooding; Clare (Cheshire, GB2), Grosveld; Franklin G. (London, GB2), Antoniou; Michael (London, GB2)
Assignee: Imperial Chemical Industries PLC (London, GB)
Application Number:08/186,895
Patent Claims:1. An expression system which comprises murine erythroleukemia cells transformed with a vector which comprises (i) the human beta-globin promoter, (ii) a genomic DNA sequence which codes for a polypeptide heterologous to said murine erythroleukemia cells and (iii) a dominant control region, and wherein after induction of differentiation of said murine erythroleukemia cells, said polypeptide is secreted by said murine erythroleukemia cells.

2. The expression system of claim 1 wherein the dominant control region comprises a micro locus which comprises a 6.5 kb fragment obtained by ligating the fragments:

2.1 kb XbaI - XbaI;

1.9 kb HindIII - HindIII;

1.5 kb KpnI - BgIII; and

1.1 kb partial SacI; from the .beta.-globin gene.

3. A method of preparing a polypeptide, said method comprising cultivating the expression system according to claim 1.

4. An expression system which comprises murine erythroleukemia cells transformed with a vector which comprises (i) the human beta-globin promoter, (ii) the second exon/intron, 3rd exon and polyadenylation sequence, all of the human beta-globin gene, (iii) a cDNA sequence which codes for a polypeptide and (iv) a dominant control region, and wherein after induction of differentiation of said murine erythroleukemia cells, said polypeptide is secreted by said murine erythroleukemia cells.

5. The expression system of claim 4 wherein the dominant control region comprises a micro locus which comprises a 6.5 kb fragment obtained by ligating the fragments:

2.1 kb XbaI - XbaI;

1.9 kb HindIII - HindIII;

1.5 kb KpnI - BgIII ; and

1.1 kb partial SacI; from the .beta.-globin gene.

6. A method of preparing a polypeptide, said method comprising cultivating the expression system according to claim 4.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9027917Dec 21, 1990

Details for Patent 5,538,885

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Imperial Chemical Industries PLC (London, GB) 2013-07-23 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Imperial Chemical Industries PLC (London, GB) 2013-07-23 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Imperial Chemical Industries PLC (London, GB) 2013-07-23 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Harvard Business School
Express Scripts
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.